Lupus & antiphospholipid syndrome
Evaluating the impact of type 2 diabetes mellitus on interstitial lung disease prevalence in patients with systemic lupus erythematosus: A national inpatient sample analysis
Main finding · ILD prevalenceResult — go to the resultOdds ratio 0.798 95% CI 0.695–0.918Authors' conclusion
Our study suggests that T2DM significantly reduced ILD risk in patients with SLE, specifically diminishing pulmonary fibrosis prevalence.
Study context
- Population
- Adult systemic lupus erythematosus (SLE) inpatients, 2019–2020 National Inpatient Sample databasepropensity score matched
- Participants
- 10,532 vs 10,532
- Exposure
- SLE with T2DM vs SLE without T2DM
- SLE + T2DM+n = 10,532
- SLE + T2DM-n = 10,532reference
- Outcome
- Interstitial lung disease (ILD) prevalence
Methodological detailspropensity score matching, multivariate logistic regression, National Inpatient Sample 2019-2020
- Propensity score matching
- Multivariate logistic regression
- National Inpatient Sample 2019-2020
Main finding
As reported in the abstract
Odds ratio
0.798
95% CI 0.695–0.918
P = 0.002
Events by group
SLE + T2DM+vs SLE + T2DM-
OR 0.798 (95% CI 0.695–0.918); P = 0.002
Observational data: associations, not effects.
Secondary outcomes
| Outcome | SLE + T2DM+ | SLE + T2DM- | OR (95% CI) | P value | |
|---|---|---|---|---|---|
| Pulmonary fibrosis | 1.3% | 1.8% | 0.7 (0.560–0.875) | P = 0.002 | |
| 0.512Odds ratio (log scale) |
Secondary outcomes: death, LOS, ARDS, pneumothorax, pleural effusion, PAH
- No differences found
Original publication
Evaluating the impact of type 2 diabetes mellitus on interstitial lung disease prevalence in patients with systemic lupus erythematosus: A national inpatient sample analysis. Lupus. Published 14 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →